Medulloblastomas are the most common malignant brain tumors in children. More than one third of children with these tumors do not survive and essentially 100% of survivors have life changing neurocognitive sequelae. New approaches to treatment with reduced toxicity are needed. In the first five years of this project, the largest medulloblastoma genomic dataset created to date was established. Using integrated analysis of molecular, genomic and clinical data, medulloblastomas were discovered to consist of multiple molecular subtypes, each with a unique molecular signature reflecting underlying mechanisms of tumorigenesis and correlated with clinical outcome. These data were used to develop the most accurate risk-stratification schema developed to date, which proved to be generalizable to a fully independent dataset. The goals of the next funding period will be to define molecular subtypes at a deeper level, to identify molecular markers for targeted therapies, and to complete the development of our risk stratification model with a goal of translating to a test with that will be incorporated into the next generation of medulloblastoma clinical trials. These goals will be accomplished through the following Specific Aims: 1) Refine and validate medulloblastoma subtyping and outcome prediction in large-scale multi-institutional prospective clinical trials;2) Implement a """"""""real time"""""""" test for risk stratification and molecular subtyping of medulloblastoma patients;and 3) Develop an interactive website, or portal, which will provide a single, web-based, publicly available gateway to deliver genomic data, genesets, and computational methodology to the general clinical and scientific community.

Public Health Relevance

The goal of this project is to understand how specific intrinsic molecules are related to the clinical behavior of medulloblastomas, the most common malignant brain tumors in children. Molecular markers will be developed to predict outcome so that conventional chemotherapy and radiation treatments can be optimized for maximal efficacy and to minimize damage to the developing brain. Molecular mechanisms will be identified to develop effective targeted therapies that may ultimately replace conventional treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA109467-06
Application #
8187220
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Timmer, William C
Project Start
2004-08-01
Project End
2016-05-31
Budget Start
2011-08-01
Budget End
2012-05-31
Support Year
6
Fiscal Year
2011
Total Cost
$748,185
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Huang, Franklin W; Mosquera, Juan Miguel; Garofalo, Andrea et al. (2017) Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov 7:973-983
Boulay, Gaylor; Awad, Mary E; Riggi, Nicolo et al. (2017) OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. Cancer Discov 7:288-301
Kim, Jong Wook; Abudayyeh, Omar O; Yeerna, Huwate et al. (2017) Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst 5:105-118.e9
Archer, Tenley C; Mahoney, Elizabeth L; Pomeroy, Scott L (2017) Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics 14:265-273
Jonas, Oliver; Calligaris, David; Methuku, Kashi Reddy et al. (2016) First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol 12:1297-302
Tamayo, Pablo; Steinhardt, George; Liberzon, Arthur et al. (2016) The limitations of simple gene set enrichment analysis assuming gene independence. Stat Methods Med Res 25:472-87
Kim, Jong Wook; Botvinnik, Olga B; Abudayyeh, Omar et al. (2016) Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol 34:539-46
Sengupta, Soma; Weeraratne, Shyamal Dilhan; Sun, Hongyu et al. (2014) ?5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol 127:593-603
Zhu, Zehua; Aref, Amir R; Cohoon, Travis J et al. (2014) Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 4:452-65
He, Xuelian; Zhang, Liguo; Chen, Ying et al. (2014) The G protein ? subunit G?s is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med 20:1035-42

Showing the most recent 10 out of 49 publications